HAWAII: AIDS Clinic Gets Late Reprieve

Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.

HAWAII: AIDS Clinic Gets Late Reprieve

Honolulu Advertiser (12.28.06) - Friday, December 29, 2006
Christie Wilson

The National Institutes of Health has agreed to a temporary cash infusion for the Hawaii AIDS Clinical Trials Unit, which had faced closure at year's end. NIH's $640,000 "bridge" funding, combined with other monies, should allow HACTU to operate for another six months, said Dr. Cecilia Shikuma, the unit's program director.

In November, HACTU was notified by NIH's National Institute of Allergy and Infectious Diseases (NIAID) that its $1.6 million grant would not come through, as several dozen clinical trial units involving HIV drugs were being shut down.

Operating within the University of Hawaii's John A. Burns School of Medicine, HACTU is the state's only research program dedicated exclusively to HIV/AIDS. But the university's 2007- 08 budget had already been decided by November, said Shikuma, who is seeking legislative support to route additional funds to the unit through allocations the state makes to the university.

State Sen. David Ige (D-16th), the Senate Health Committee's chairperson, said he is talking with university officials to determine where the unit "stacks up as a priority." Ige said he is encouraging his colleagues to support "this important program."

In addition to support from the Legislature, which begins its session next month, Shikuma said she has the support of Gov. Linda Lingle and Hawaii's congressional delegation in lobbying NIAID not to cut HACTU's grant. NIAID officials said no grant cuts have been finalized.

HACTU has participated in 275 clinical drug trials involving 1,000 patients. Its Clint Spencer Clinic at Le'ahi Hospital treats 300-350 patients, and physicians travel to the Big Island to see patients who lack access to medical care.
061229
AD062519

Copyright © 2006 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.